Capstan Therapeutics announces first participants dosed in its Phase 1 trial of lead in vivo CAR-T therapy, CPTX2309, for treating autoimmune disease.

Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to ...

The presentations will highlight the clinical trial design for MT-303 and preliminary translational findings for MT-302 – the company's lead in vivo mRNA CAR therapies, which together signify a ...

Below is a chart showing MRNA's trailing twelve month trading history, with the $30 strike highlighted in orange: And Avis Budget Group Inc (Symbol: CAR) options are showing a volume of 10,696 ...

By reprogramming myeloid cells using mRNA, researchers can equip them to detect and kill cancer cells with unprecedented precision.

In both syngeneic and humanized tumor models, systemic administration of anti-GPC3 CAR mRNA/LNP significantly reduced tumor burden and suppressed metastasis to the liver. The therapy was well ...